Loading…

Diagnostic Value of Oligoclonal Bands in Children: A Nationwide Population-Based Cohort Study

We evaluated the diagnostic value of cerebrospinal fluid oligoclonal bands in individuals less than 18 years of age. In a nationwide population-based setting, we retrieved data on 2055 children's oligoclonal band examination, including concordant cerebrospinal fluid biomarkers, during 1994 to 2...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric neurology 2019-08, Vol.97, p.56-63
Main Authors: Boesen, Magnus Spangsberg, Born, Alfred Peter, Jensen, Poul Erik Hyldgaard, Sellebjerg, Finn, Blinkenberg, Morten, Lydolph, Magnus Christian, Jørgensen, Mikala Klok, Rosenberg, Lene, Thomassen, Jesper Qvist, Børresen, Malene Landbo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the diagnostic value of cerebrospinal fluid oligoclonal bands in individuals less than 18 years of age. In a nationwide population-based setting, we retrieved data on 2055 children's oligoclonal band examination, including concordant cerebrospinal fluid biomarkers, during 1994 to 2017. Case ascertainment was by review of medical records and diagnostic codes. We used Fisher's exact test to explore distribution differences of oligoclonal band positivity in acquired demyelinating syndromes (ADS) before and after age 12 years and calculated the sensitivity, specificity, positive predictive value, and negative predictive value of oligoclonal bands to distinguish ADS from the other diagnostic groups. Median age at oligoclonal band examination was 15.2 years (range = 1.8 to 18.0), and 10% had presence of cerebrospinal fluid oligoclonal bands. Oligoclonal band positivity was the highest in ADS (52%), but it was age dependent: 21% in children with ADS before age 12 years and 68% in children aged 12 through 17 years (P 
ISSN:0887-8994
1873-5150
DOI:10.1016/j.pediatrneurol.2019.03.002